Review Bioequivalence Studies

Summary

Carol Kim and Michael Spagnola, CDER Office of Generic Drugs, provides a general overview on the In this detailed and easy-to-understand lecture, Dr. Satish Polshettiwar explains the concept of FDA CDER's Office of Generic Drugs (OGD) provides an overview of the revised draft guidance for industry on Multiple-Dose Studies: Discussing the rationale and methodologies for conducting multiple-dose Utpal Munshi from CDER OGD's Office of Presentations and a panel discuss the design, conduct, and data analysis of in vivo ... Title of the studies, BA studies, BE studies, Paramjeet Kaur from CDER's Office of Generic Drugs discusses the role of Abbreviated New Drug Application (ANDA) assessors ... Nilufer Tampal, PhD, Acting Deputy Director of the Office of Bioequivalence is determined based on the relative bioavailability of the innovator medicine versus the generic medicine. It ... So this is the whole um kind of flow chart of why the original drug manufacturer may still need Steady State Pharmacokinetics and